Drugs / 177Lu-DOTA-EB-FAPI
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05410821 | Jun 2022 → Jun 2024 | thyroid Hurthle cell carcinoma, thyroid gland papillary carcinoma | The First Affiliated Hospital of Xiamen University | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05963386 | Feb 2022 → Sep 2024 | refractory malignant neoplasm | The First Affiliated Hospital of Xiamen University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-DOTA-EB-FAPI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05410821 ↗ |
| Action | Inhibit | “a long-lasting radiolabeled fibroblast activation protein inhibitor 177Lu-DOTA-EB-FAPI” NCT05410821 ↗ |
| Modality | Other / unclassified | “radioligand therapy” NCT05410821 ↗ |
| Route | Intravenous | “Slow intravenous infusion/injection (i.v.)” NCT05410821 ↗ |